Gastrointestinal tract post-transplant lymphoproliferative disorder after liver transplantation
Qin-Fen Xie, Ping Chen, Xin-Hua Chen, Ji-Min Liu, Jan Lerut and Shu-Sen Zheng
Department of Hepatobiliary and Pancreatic Surgery (Xie QF) and Department of Infectious Disease (Chen P), Shulan (Hangzhou) Hospital (Zhejiang University International Hospital), Hangzhou 310000, China; Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health; Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China (Chen XH and Zheng SS); Department of Pathology and Molecular Medicine, Faculty of Health Science, McMaster University, Hamilton, Ontario, Canada (Liu JM); Starzl Unit of Abdominal Transplantation, Université catholique Louvain (UCL), Brussels, Belgium (Lerut J)
Corresponding Author: Shu-Sen Zheng
(Email: shusenzheng@zju.edu.cn)
Abstract：To the Editor:
Post-transplant lymphoproliferative disorder (PTLD) is a rare and potentially fatal complication occurring after all types of solid organ transplantation.[1] PTLD accounts for 20% of all de novo post-transplant tumors.[2, 3] The most important risk factors for PTLD are prolonged intense immunosuppression and Epstein-Barr virus (EBV) infection.[4] The gastrointestinal (GI) tract is the most frequently involved site (GI-PTLD), the liver allograft itself can also be involved.[5] As clinical manifestations of PTLD may vary, early diagnosis of PTLD is often difficult.[6, 7]
2017, Vol. 16 
